BR112016023833A2 - compostos, composições, métodos e uso para tratar ou prevenir infecções por vírus da hepatite c - Google Patents
compostos, composições, métodos e uso para tratar ou prevenir infecções por vírus da hepatite cInfo
- Publication number
- BR112016023833A2 BR112016023833A2 BR112016023833A BR112016023833A BR112016023833A2 BR 112016023833 A2 BR112016023833 A2 BR 112016023833A2 BR 112016023833 A BR112016023833 A BR 112016023833A BR 112016023833 A BR112016023833 A BR 112016023833A BR 112016023833 A2 BR112016023833 A2 BR 112016023833A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- treating
- compounds
- methods
- virus infections
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 208000010710 hepatitis C virus infection Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461980016P | 2014-04-15 | 2014-04-15 | |
| PCT/US2015/025903 WO2015160907A2 (en) | 2014-04-15 | 2015-04-15 | Potent and selective inhibitors of hepatitis c virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016023833A2 true BR112016023833A2 (pt) | 2017-10-10 |
Family
ID=54324704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016023833A BR112016023833A2 (pt) | 2014-04-15 | 2015-04-15 | compostos, composições, métodos e uso para tratar ou prevenir infecções por vírus da hepatite c |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9926295B2 (enExample) |
| EP (1) | EP3131892A4 (enExample) |
| JP (1) | JP2017513852A (enExample) |
| KR (1) | KR20170002407A (enExample) |
| CN (1) | CN106661004A (enExample) |
| AU (1) | AU2015247706A1 (enExample) |
| BR (1) | BR112016023833A2 (enExample) |
| CA (1) | CA2945514A1 (enExample) |
| IL (1) | IL248318A0 (enExample) |
| MX (1) | MX2016013434A (enExample) |
| PH (1) | PH12016502039A1 (enExample) |
| RU (1) | RU2016144076A (enExample) |
| SG (1) | SG11201608587QA (enExample) |
| WO (1) | WO2015160907A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US9775831B2 (en) | 2013-07-17 | 2017-10-03 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of HCV |
| WO2015184644A1 (zh) * | 2014-06-06 | 2015-12-10 | 爱博新药研发(上海)有限公司 | 抑制丙肝病毒的化合物、药物组合物及其应用 |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US11752166B2 (en) | 2018-05-09 | 2023-09-12 | Cocrystal Pharma, Inc. | Combination therapy for treatment of HCV |
| CN109456375B (zh) * | 2018-12-11 | 2019-10-22 | 枣庄学院 | 一种抑制丙肝病毒的含单糖基杂环类化合物及制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2715839C (en) * | 2008-02-13 | 2014-12-09 | Bristol-Myers Squibb Company | Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors |
| BRPI1005401A2 (pt) * | 2009-02-06 | 2019-04-02 | Rfs Pharma, Llc | pro-farmácos de purina nucleosídeo monofosfato para o tratamento de câncer e infecções virais |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2809261A1 (en) * | 2010-08-26 | 2012-03-01 | Rfs Pharma, Llc | Potent and selective inhibitors of hepatitis c virus |
| WO2012048421A1 (en) * | 2010-10-14 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| AU2011323658A1 (en) * | 2010-11-01 | 2013-05-23 | Genoscience Pharma | Novel specific HCV NS3 protease inhibitors |
-
2015
- 2015-04-15 EP EP15779578.2A patent/EP3131892A4/en not_active Withdrawn
- 2015-04-15 BR BR112016023833A patent/BR112016023833A2/pt active Search and Examination
- 2015-04-15 US US15/303,277 patent/US9926295B2/en active Active
- 2015-04-15 CA CA2945514A patent/CA2945514A1/en not_active Abandoned
- 2015-04-15 KR KR1020167030815A patent/KR20170002407A/ko not_active Withdrawn
- 2015-04-15 AU AU2015247706A patent/AU2015247706A1/en not_active Abandoned
- 2015-04-15 MX MX2016013434A patent/MX2016013434A/es unknown
- 2015-04-15 JP JP2016562874A patent/JP2017513852A/ja active Pending
- 2015-04-15 WO PCT/US2015/025903 patent/WO2015160907A2/en not_active Ceased
- 2015-04-15 CN CN201580032237.0A patent/CN106661004A/zh active Pending
- 2015-04-15 RU RU2016144076A patent/RU2016144076A/ru unknown
- 2015-04-15 SG SG11201608587QA patent/SG11201608587QA/en unknown
-
2016
- 2016-10-12 PH PH12016502039A patent/PH12016502039A1/en unknown
- 2016-10-13 IL IL248318A patent/IL248318A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201608587QA (en) | 2016-11-29 |
| JP2017513852A (ja) | 2017-06-01 |
| IL248318A0 (en) | 2016-11-30 |
| WO2015160907A2 (en) | 2015-10-22 |
| AU2015247706A1 (en) | 2016-10-27 |
| WO2015160907A3 (en) | 2016-12-01 |
| MX2016013434A (es) | 2017-03-03 |
| US20170029407A1 (en) | 2017-02-02 |
| CN106661004A (zh) | 2017-05-10 |
| EP3131892A2 (en) | 2017-02-22 |
| KR20170002407A (ko) | 2017-01-06 |
| PH12016502039A1 (en) | 2017-01-09 |
| CA2945514A1 (en) | 2015-10-22 |
| US9926295B2 (en) | 2018-03-27 |
| EP3131892A4 (en) | 2017-09-20 |
| RU2016144076A (ru) | 2018-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3139954A4 (en) | Methods and compositions for treating hepatitis b virus infections | |
| DK3805376T3 (da) | Modificeret virus | |
| SI3349758T1 (sl) | Postopki za zdravljenje okužb z virusom arenaviridae | |
| PT3407888T (pt) | Compostos de piridopirroloquinoxalina, suas composições e utilizações | |
| BR112016015706A2 (pt) | composto, uso do mesmo e composição farmacêutica | |
| MX373703B (es) | Derivados de azepano y metodos para tratar infecciones por hepatitis b. | |
| EP3497209A4 (en) | CHEMERICAL POXVIRUS COMPOSITIONS AND THEIR USES | |
| BR112016030787A2 (pt) | entidade química, composição farmacêutica e seu uso | |
| DK3565568T3 (da) | Ændret virus | |
| LT3594238T (lt) | Antikūno kompozicijos, skirtos navikų gydymui | |
| DK3191489T3 (da) | Pyrrolopyrimidiner til anvendelse ved influenzavirusinfektion | |
| HRP20180639T1 (hr) | Derivati izoindolina, namijenjeni upotrebi u liječenju virusne infekcije | |
| DK3261642T3 (da) | Quinolinderivater til anvendelse ved behandling eller forebyggelse af virusinfektioner | |
| LT3436074T (lt) | Tiazolido junginiai, skirti virusinių infekcijų gydymui | |
| PL3400269T3 (pl) | Zastosowanie 4-bora-3a,4a-diaza-s-indacenów do zabezpieczania | |
| BR112016023833A2 (pt) | compostos, composições, métodos e uso para tratar ou prevenir infecções por vírus da hepatite c | |
| EP3560512A4 (en) | COMPOSITION OF VACCINE AGAINST ZONA | |
| GB2546984B (en) | Preventing clean files being used by malware | |
| PT3551619T (pt) | Composições compreendendo profármacos de metilfenidato, processos de preparação e utilização dos mesmos | |
| EP3166637A4 (en) | Compositions and methods for treating dengue virus infection | |
| BR112017027770A2 (pt) | composições e métodos para modular infecção viral | |
| EP3625349A4 (en) | MODIFIED VIRUSES | |
| HUE056414T2 (hu) | Triptofán-2,3-dioxigenázt vagy annak fragmentumait tartalmazó vakcinakészítmények | |
| IL246643B (en) | Compositions and kits for treating human immunodeficiency virus/accquired immunodeficiency syndrome | |
| EP3500280A4 (en) | VIRUS VACCINES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2562 DE 2020-02-11 |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |